Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Pancreatic Neoplasms 42Neoplasms 17Neoplasm Metastasis 15Carcinoma, Non-Small-Cell Lung 14Breast Neoplasms 14Ovarian Neoplasms 11Triple Negative Breast Neoplasms 6Stomach Neoplasms 6Lung Neoplasms 6Melanoma 5Fallopian Tube Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Peritoneal Neoplasms 4Lymphoma, Non-Hodgkin 4Hodgkin Disease 4Carcinoma, Pancreatic Ductal 4Adenocarcinoma 4Recurrence 3Rectal Neoplasms 3Prostatic Neoplasms 3Lymphoma 3Head and Neck Neoplasms 3Gallbladder Neoplasms 3Endometrial Neoplasms 3Colorectal Neoplasms 3Urinary Bladder Neoplasms 2Unspecified Adult Solid Tumor, Protocol Specific 2Small Cell Lung Carcinoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Lymphoma, B-Cell 2

Interventions

pembrolizumab 1Sirolimus 1Nivolumab 1Ipilimumab 1Docetaxel 1Albumin-Bound Paclitaxel 1ADI PEG20 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Advanced Solid Cancers × Albumin-Bound Paclitaxel × Clear all
NCT00337376 2014-01-14

A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers

Yale University

Phase 1 Terminated
23 enrolled

Advanced Solid Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡